Issue 10, 2012

Analogues of the HIV-Tat peptide containing Nη-modified arginines as potent inhibitors of protein arginine N-methyltransferases

Abstract

A series of Nη-modified peptides based upon the arginine-rich motif of the HIV-Tat peptide were synthesised and evaluated as substrates and inhibitors of three members of the protein arginine N-methyltransfferase (PRMT) family. PRMT1 and PRMT6 were shown to methylate each of the Tat-peptide analogues tested while PRMT4/CARM1 displayed a lower methylation activity against the same series of peptides. Kinetic assays further revealed that the Tat-peptide analogues also behave as potent substrate-inhibitors of PRMT1 and PRMT6 over specific enzyme concentration ranges. This work provides new insights into the methylating activity and inhibition of PRMTs when interacting with highly positively charged, multiple-arginine-containing peptides.

Graphical abstract: Analogues of the HIV-Tat peptide containing Nη-modified arginines as potent inhibitors of protein arginine N-methyltransferases

Supplementary files

Article information

Article type
Concise Article
Submitted
20 Jun 2012
Accepted
20 Jul 2012
First published
30 Jul 2012

Med. Chem. Commun., 2012,3, 1235-1244

Analogues of the HIV-Tat peptide containing Nη-modified arginines as potent inhibitors of protein arginine N-methyltransferases

P. 't Hart, D. Thomas, R. van Ommeren, T. M. Lakowski, A. Frankel and N. I. Martin, Med. Chem. Commun., 2012, 3, 1235 DOI: 10.1039/C2MD20161E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements